8-K: Pulmonx Reports Q3 2025 Results, Updates Full-Year Outlook

Pulmonx Corporation announced its third quarter 2025 financial results, reporting a 5% increase in worldwide revenue and reaffirming its commitment to profitable growth.

Summary

• Worldwide revenue for the third quarter of 2025 reached $21.5 million, marking a 5% increase year-over-year (4% on a constant currency basis).
• International revenue grew by 15% year-over-year to $7.5 million (9% on a constant currency basis), while U.S. revenue increased by 1% to $14.0 million.
• Gross margin improved to 75% in Q3 2025, up from 74% in the same period last year, with gross profit at $16.1 million.
• Operating expenses rose by 4% to $30.4 million, driven by increased clinical, development, and commercial investments.
• Net loss for the quarter was $14.0 million, or $0.34 per share, a slight improvement from a net loss of $14.1 million, or $0.36 per share, in Q3 2024.
• Adjusted EBITDA loss was $8.2 million, compared to $8.1 million in the prior year's third quarter.
• Cash and cash equivalents stood at $76.5 million as of September 30, 2025.
• The company updated its full-year 2025 revenue outlook to a range of $89 million to $90 million, with an expected gross margin of approximately 73%.
• Full-year 2025 operating expenses are projected to be between $125 million and $126 million, including about $21 million in non-cash stock-based compensation.
• Glen French was reappointed as President and Chief Executive Officer, and Derrick Sung was appointed as Chief Operating Officer and Chief Financial Officer.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company continues to incur losses, revenue growth is solid, especially internationally, and gross margin improved. Management's comments indicate performance met expectations and a commitment to 'sustainable, profitable growth' through 'refine execution,' suggesting a stable but evolving operational strategy. The updated guidance provides clarity for the remainder of the year.

Positives

• Worldwide revenue increased by 5% year-over-year to $21.5 million, demonstrating continued growth.
• International revenue showed strong growth of 15% year-over-year to $7.5 million, indicating successful global adoption.
• Gross margin improved to 75% in Q3 2025 from 74% in Q3 2024, reflecting better cost management or pricing.
• Net loss per share improved slightly to $0.34 from $0.36 in the prior year, despite increased investments.
• Reappointment of Glen French as CEO and appointment of Derrick Sung as COO and CFO could signal strengthened leadership and strategic focus.

Negatives

• U.S. revenue growth was modest at 1% year-over-year, suggesting slower domestic market expansion.
• Operating expenses increased by 4% to $30.4 million due to higher clinical, development, and commercial investments, impacting profitability.
• Adjusted EBITDA loss slightly worsened to $8.2 million from $8.1 million in the comparable prior period.
• The company continues to operate at a net loss and adjusted EBITDA loss, indicating it is not yet profitable.

Risks

• The updated 2025 financial guidance does not account for potential impacts from future tariffs or trade policy changes.
• The guidance also excludes effects on the global macroeconomic environment, including foreign currency fluctuations.
• Forward-looking statements are subject to numerous risks and uncertainties, as detailed in the Risk Factors section of Pulmonx's public filings, including the Form 10-Q filed on August 1, 2025.

Future Outlook

Pulmonx is updating its full-year 2025 financial outlook, expecting total revenue to be in the range of $89 million to $90 million. The company anticipates a gross margin of approximately 73% and total operating expenses between $125 million and $126 million, which includes about $21 million in non-cash stock-based compensation. This guidance does not factor in potential impacts from future tariffs, trade policy changes, or global macroeconomic conditions, including foreign currency fluctuations.

Management Comments

• "While our third quarter performance broadly met expectations, we feel there is a meaningful opportunity to leverage our operational foundation and refine execution to expand Zephyr Valve treatment volumes."
• "We remain steadfast in our mission to improve the quality of life for patients with severe emphysema and are committed to acting with discipline to ensure our investments and operations are aligned with our goal to achieve sustainable, profitable growth."

Industry Context

Pulmonx operates as a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), specifically targeting severe emphysema patients with its Zephyr Endobronchial Valve. The reported revenue growth, particularly internationally, reflects continued commercial execution and global adoption of its 'standard of care' Zephyr Valve procedures, indicating a positive trend within the specialized lung disease treatment market.

Comparison to Industry Standards

• Not provided in the filing. The filing does not offer specific comparable companies, projects, or results to assess against global benchmarks.

Management Changes

Stakeholder Impact

• Shareholders: Impacted by financial performance, updated guidance, and management changes, which could influence stock valuation.
• Patients: The company's continued focus on expanding Zephyr Valve treatment volumes aims to improve the quality of life for patients with severe emphysema.
• Employees: Increased clinical, development, and commercial investments suggest ongoing activity and potential growth opportunities within the company.

Next Steps

• Host a conference call on November 12, 2025, at 1:30 p.m. PT / 4:30 p.m. ET to discuss third quarter financial results.
• Archive the webcast of the conference call on the company's investor relations website.

Key Dates

Recommendation

Pulmonx demonstrates consistent revenue growth, particularly in international markets, and an improving gross margin, which are positive indicators. However, the company continues to operate at a net loss and adjusted EBITDA loss, and operating expenses are increasing due to investments. While management states Q3 performance 'broadly met expectations' and commits to 'sustainable, profitable growth,' the path to profitability is not yet clear. The significant management changes could be a catalyst for future performance, but current results do not warrant a 'buy' given the ongoing losses, nor a 'sell' given the growth and strategic investments. A 'hold' recommendation allows investors to observe the execution of the refined strategy and progress towards profitability.

Keywords

Pulmonx, LUNG, Q3 2025 Earnings, Financial Results, Revenue Growth, Gross Margin, Net Loss, Adjusted EBITDA, Zephyr Valve, COPD Treatment, Medical Devices, Minimally Invasive, Management Changes, Financial Outlook